The Event. Buried in Item 2 of this morning’s 10-Q — not a press release, not an 8-K headline — is the sentence that just re-rated this stock 58%: “we plan to submit an amendment to our BLA that includes the 24-month open-label extension data from our HOPE-3 study, along with additional analyses of the existing data package, in order to support a refined indication focused on the primary endpoint. FDA has indicated it is willing to review this amendment and, upon receipt, to extend the PDUFA action date accordingly.”
The Second Event. A Schedule 13G/A filed the same day puts Tang Capital Management at 4,099,900 shares — 7.1% of the 57,911,893 outstanding, event date June 30, 2026. That is now the largest disclosed holder in the name, ahead of BlackRock’s ~6.5% index stake and RA Capital’s 5.2%.
The Reaction. From $4.21 to $6.65 — up 58.0% in a single session, off a base that was trading below the $237.9M cash balance yesterday. The market spent three weeks pricing a CRL on August 22. This morning it learned there may not be an August 22.
The narrow path became the company’s official plan. On July 30, after the 9-3 panel vote, I wrote that the remaining route was “a skeletal-only label with cardiac claims stripped, plausibly with a confirmatory-trial requirement.” Capricor is now formally pursuing exactly that — a refined indication focused on the primary endpoint, PUL v2.0. The implication: the company has stopped trying to defend the cardiomyopathy claim the panel just rejected 3-for/9-against and is re-cutting the ask to the one endpoint that held. That is the correct strategic move, and it is the first time management’s stated plan and the evidence base have been pointed in the same direction since June.
FDA said it is willing to review — and to extend. A CRL on August 22 was the modal outcome eight days ago. An agreed amendment plus an extension converts a hard binary into a process. Why it matters: you do not get a rejection letter on a date that no longer exists. The agency agreeing to look at new data rather than closing the file is a meaningfully different posture than the one the briefing documents implied on July 27. It is not approval, and it is not a signal that FDA has changed its mind on the cardiac question — it is the agency leaving a door open on the skeletal question.
The new data is 24-month open-label extension. HOPE-3’s published result is 12 months. The amendment adds a second year of follow-up from the OLE. Why it matters: the single most common critique of a 1.2-point PUL v2.0 difference is that it’s a small effect measured over a short window in a slowly progressive disease. Durability is the only way to answer that critique — a treatment effect that widens or holds at 24 months is a categorically stronger argument than the same effect at 12.
Tang Capital at 7.1%. 4,099,900 shares across TCP, TCPI, TCP III and TCP IV, event date June 30, 2026 — before the briefing-book collapse, before the AdCom. This is not a fund that showed up for the bounce. The implication: Kevin Tang’s franchise is known for hard-nosed valuation work in beaten-down and asset-value situations, and its arrival alongside RA Capital’s 5.2% means two specialist franchises now hold ~12.3% of a company whose bear case I built partly on “no conviction money is here.” That leg of the bear case is now comprehensively retired.
Mesoblast is suing. On July 16, Mesoblast International filed a patent infringement and declaratory judgment action in the District of Delaware, asserting three patents on mesenchymal stem cell compositions, preparations and methods, and seeking injunctive relief and damages. New, and unpriced. In the original deep dive I argued the practical moat for a living-cell allogeneic product is manufacturing know-how plus regulatory exclusivity rather than the patent docket. That cuts both ways — a competitor’s composition patents are exactly the kind of claim that is hard to design around in cell therapy. Add it to the securities class actions (a new one filed July 30) and derivative suits (another filed August 7) stacking on the G&A line.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.